Connor Clark & Lunn Investment Management Ltd. Reduces Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Connor Clark & Lunn Investment Management Ltd. trimmed its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 76.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,327 shares of the life sciences company's stock after selling 178,735 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.07% of Integra LifeSciences worth $1,277,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV raised its position in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter worth about $180,000. Centiva Capital LP purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth about $192,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth about $198,000. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average target price of $23.00.

Remove Ads

Integra LifeSciences Stock Down 1.0 %

Shares of NASDAQ:IART traded down $0.22 during trading hours on Friday, hitting $22.49. The company's stock had a trading volume of 1,115,762 shares, compared to its average volume of 1,008,152. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $35.49. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -249.86, a P/E/G ratio of 0.73 and a beta of 1.23. The firm's fifty day moving average price is $23.85 and its 200 day moving average price is $22.05.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.89 EPS. As a group, research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.